cancer vaccine news from FierceVaccines
News
Analysts buoy Cell Genesys' hope for GVAX
Shares of Cell Genesys got hit hard last week after the company announced that it was Read more...
Cell Genesys' cancer vax setback depresses field
Back in 2000, shares of Cell Genesys traded at more than $50 a share. Yesterday, the stock closed under $1 after plummeting more than 70 percent after its prostate cancer vaccine trial was halted due Read more...
Kennedy's best hope may lie in cancer vaccine trial
The general prognosis for anyone diagnosed with malignant glioma is poor. The most common form is glioblastoma multiforme, which swiftly dispatches cancer cells throughout the brain. Patients Read more...
Tiny Antigenics gears up to market cancer vaccine
After spending 12 years and $425 millions of dollars in a so far unsuccessful quest to win FDA approval of Oncophage, tiny Read more...
VaxDesign offers an alternative to animal studies
Time magazine profiles the work of VaxDesign, a five-year-old biotech company that has developed simulated human immune systems, mixing blood cells and faux tissue into a special construct that can Read more...
Get more cancer vaccine coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets